Annual Report 2023

40 40 China Merchants China Direct Investments Limited Annual Report 2023 INVESTMENT MANAGER’S DISCUSSION AND ANALYSIS (CONTINUED) SUB-PARTICIPATION SCHEME (CONTINUED) Name of projects Original investment amount of the Fund Original amounts actually paid by the Participants Relative proportion US$* US$* Huashun Xin’an (1st installment capital contribution for 1st round capital injection) 3,669,220 18,510 0.504% Huashun Xin’an (2nd installment capital contribution for 1st round capital injection) 927,190 4,630 0.504% Huiyou Xingyao Fund (2nd installment capital contribution) 1,187,000 7,030 0.603% CASREV Fund III (3rd installment capital contribution) 1,931,490 2,580 0.140% Xinyi 5,416,700 23,150 0.427% Xunfei Healthcare (2nd round capital injection) 7,804,570 19,250 0.247% Azuri 4,724,560 24,370 0.516% Huashun Xin’an (2nd round capital injection) 1,020,090 11,470 1.125% CASREV Fund III (4th installment capital contribution) 1,816,810 2,580 0.140% Immvira 8,000,000 21,660 0.271% Hanwei 7,016,070 30,780 0.439% Moonshot AI 10,000,000 38,430 0.384% * Calculated with prevalent exchange rates at the time of the amounts paid